A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

Completed · Phase 2

Conditions studied: AL Amyloidosis

In brief

AL amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine the recommended dose of CAEL-101 to facilitate progression of further clinical trials and evaluate safety and tolerability of CAEL-101 in combination with the standard of care (SoC) cyclophosphamide-bortezomib-dexamethasone (CyBorD) chemotherapy and daratumumab .

Key facts

Study ID
NCT04304144
Run by
Alexion Pharmaceuticals, Inc.
People needed
25
Starts
2020-03-18
Expected to finish
2023-11-14
Last updated by the study team
2025-03-05

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.